• The risk of tumor lysis syndrome (TLS) is a continuum based on multiple factors, including tumor burden and comorbidities. Reduced renal function (creatinine clearance [CLcr] <80 mL/min) further increases the risk
  •  Changes in blood chemistries consistent with TLS that require prompt management can occur as early as 6 to 8 hours following the first dose and each dose increase